| 國立成功大學 |
2023 |
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
|
Hartmaier, R.J.;Markovets, A.A.;Ahn, M.J.;Sequist, L.V.;Han, J.-Y.;Cho, B.C.;Yu, H.A.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.-S.;Su, W.-C.;Kowalski, D.M.;Orlov, S.;Ren, S.;Frewer, P.;Ou, X.;Cross, D.A.E.;Kurian, N.;Cantarini, M.;J�nne, P.A. |
| 國立成功大學 |
2023 |
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
|
Sequist, L.V.;Yang, J.C.-H.;Yamamoto, N.;O'Byrne, K.;Hirsh, V.;Mok, T.;Geater, S.L.;Orlov, S.;Tsai, C.-M.;Boyer, M.;Su, W.-C.;Bennouna, J.;Kato, T.;Gorbunova, V.;Lee, K.H.;Shah, R.;Massey, D.;Zazulina, V.;Shahidi, M.;Schuler, M. |
| 國立成功大學 |
2023 |
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
|
Yang, J.C.-H.;Su, W.-C.;Chiu, Chiu C.-H.;Shiah, H.-S.;Lee, K.-Y.;Hsia, T.-C.;Uno, M.;Crawford, N.;Terakawa, H.;Chen, W.-C.;Takayama, G.;Hsu, C.;Hong, Y.;Saintilien, C.;McGill, J.;Chang, G.-C. |
| 臺大學術典藏 |
2022-09-15T01:09:03Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Chia-Chi Lin; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-09-15T01:09:01Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Chia-Chi Lin; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-09-15T01:08:54Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Chia-Chi Lin; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-09-15T01:08:50Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
|
Liao B.-C.; Hsu W.-H.; Lee J.-H.; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Chia-Chi Lin; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:51Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lai M.-S.; Yang J.C.-H.; Cheng A.-L.; Hsu C.-H.; Kuo R.N.-C.; Yeh Y.-C.; Shao Y.-Y.; CHIUN HSU; Shau W.-Y.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-08-19T00:20:45Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Yang J.C.H.; Lai M.-S.; Cheng A.-L.; Cheng W.-F.; CHIUN HSU; Shao Y.-Y.; Yang Y.-Y.; Lai C.-L.; Shau W.-Y.; Kuo R.; Lin Z.-Z.; Kuo H.-Y. |
| 臺大學術典藏 |
2022-07-26T08:09:28Z |
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens
|
Ma W.-L.; Lin C.-C.; Hsu F.-M.; Lee J.-M.; Chen J.-S.; Huang Y.-L.; YIH-LEONG CHANG; Chang C.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-06-27T07:07:27Z |
Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum
|
Liao W.-Y.; Shih J.-Y.; Chang G.-C.; Cheng Y.-K.; Yang J.C.-H.; Chen Y.-M.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-06-27T07:02:08Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; Yang P.-C.; Miller V.A. |
| 臺大學術典藏 |
2022-06-27T07:01:58Z |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
|
Liao W.-Y.; Chen J.-H.; Wu M.; Shih J.-Y.; Chen K.-Y.; Ho C.-C.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-06-27T07:01:52Z |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Tsai T.-H.; Yang C.-Y.; Ho C.-C.; Liao W.-Y.; Jan I.-S.; Chen K.-Y.; Wang J.-Y.; Ruan S.-Y.; CHONG-JEN YU; Yang J.C.H.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2022-06-27T07:01:50Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Lee J.-H.; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; CHONG-JEN YU; Shih J.-Y.; Lin C.-C.; Chen K.-Y.; Ho C.-C.; Laio W.-Y.; Yang P.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-06-27T07:01:50Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; Chang Y.-L.; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; CHONG-JEN YU; Yang J.C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:01:45Z |
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer
|
Lin Y.-T.; Wang Y.-F.; Yang J.C.-H.; CHONG-JEN YU; Wu S.-G.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:01:42Z |
Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis
|
Hsu C.-L.; Chen J.-H.; Chen K.-Y.; Shih J.-Y.; Yang J.C.H.; CHONG-JEN YU; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:01:38Z |
Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion
|
Tsai T.-H.; Wu S.-G.; Hsieh M.-S.; CHONG-JEN YU; Yang J.C.H.; Shih J.-Y. |
| 臺大學術典藏 |
2022-06-27T07:01:36Z |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|
Yang J.C.-H.; Sequist L.V.; Geater S.L.; Tsai C.-M.; Mok T.S.K.; Schuler M.; Yamamoto N.; CHONG-JEN YU; Ou S.H.I.; Zhou C.; Massey D.; Zazulina V.; Wu Y.-L. |
| 臺大學術典藏 |
2022-06-27T07:00:28Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
Liao B.-C.; Lee J.-H.; Lin C.-C.; Chen Y.-F.; Chang C.-H.; Ho C.-C.; Shih J.-Y.; CHONG-JEN YU; Yang J.C.-H. |
| 臺大學術典藏 |
2022-06-27T07:00:26Z |
Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations
|
Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; Chang Y.-L.; CHONG-JEN YU; Yang J.C.-H.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2022-06-27T07:00:23Z |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
|
Wu S-G.; Liu Y.-N.; Tsai M.-F.; Chang Y.-L.; CHONG-JEN YU; Yang P.-C.; Yang J.C.-H.; Wen Y.-F.; Shih J.-Y. |
| 臺大學術典藏 |
2022-06-27T07:00:22Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; Yu K.-L.; Ho C.-C.; Shih J.-Y.; CHONG-JEN YU; Yang J.C.H.; Rosell R.; Yang P.-C. |
